Bristol-Myers Squibb
Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BMY
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.
BMY Key Statistics
Stock Snapshot
As of today, Bristol-Myers Squibb(BMY) shares are valued at $47.14. The company's market cap stands at 95.81B, with a P/E ratio of 15.89 and a dividend yield of 5.3%.
As of 2025-11-19, Bristol-Myers Squibb(BMY) stock has fluctuated between $47.14 and $47.17. The current price stands at $47.14, placing the stock 0.0% above today's low and -0.1% off the high.
The Bristol-Myers Squibb(BMY)'s current trading volume is 8.57K, compared to an average daily volume of 13.2M.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.
During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $63.33 at its peak.
BMY News
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Bristol-Myers Squibb (BMY) shares have had a mixed performance over the past month, gaining around 7%. Investors are closely watching revenue trends and profit...
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb. The associated price target remains the same with $36.00. Mee...
Analyst ratings
70%
of 30 ratingsMore BMY News
Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Low PE Investor m...
Bristol Myers Squibb & Co. (NYSE:BMY) , in collaboration with Johnson & Johnson (NYSE:JNJ) , announced Friday that they decided to stop the Phase 3 Librexia ACS...
